BioSpace News Archive

Aytu BioPharma, Inc. announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.

Vaxart, Inc. announced that on May 17, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 22,500 shares of its common stock to one new non-executive employee to induce him to accept employment with Vaxart.

23andMe Holding Co., a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024, which ended March 31, 2024.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced data from the planned interim analysis of the exploratory open-label Phase 2a clinical study of SPN-817 for treatment-resistant seizures.

Genelux Corporation, a late clinical-stage immuno-oncology company, announced that it has commenced an underwritten public offering of its common stock and accompanying warrants.

Spruce Biosciences, Inc will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 5:00 p.m. ET.

Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”).

Beyond Air, Inc. today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2024 on Monday, June 24, 2024.

Materna Medical, Inc. has announced the completion of the first close of a $20 million Series B2 financing round. The round was led by InnovaHealth Partners and other key existing investors included Wavemaker Three-Sixty Health, Kimera Limited, Women’s Venture Capital Fund, Golden Seeds, Band of Angels, and Houston Angel Network.

Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2024 Annual Meeting of Stockholders on Wednesday, May 29, 2024, at 9:00 a.m. PT.